PLUR (Pluri Inc) Future Price to Earnings

Corporate emblem and logo of Pluristem Therapeutics (PLUR)

The forward P/E of Pluri Inc. (PLUR) exhibits volatility, as the success of Pluri Inc. depends on the commercialization of placental technologies and test results. Growth is supported by a proprietary 3D cell expansion platform, which creates a barrier to entry for competitors. However, high R&D costs and dependence on clinical trials create risks. The current value of the indicator reaches 0.00, reflecting the market valuation of future earnings.

PLUR - Pluri Projected Price to Earnings Ratio over the range 04/28/2023 - 11/13/2026

Analytical breakdowns for Pluri Inc.

- current price and projected stock value:
General company analysis:PLUR Pluri
Brand item of Pluri Inc

Forward P/E determines the market value of a stock relative to expected net income, allowing an investor to assess the asset's degree of overbought status or its growth potential if optimistic forecasts materialize. When analyzing the projected P/E multiple of the company, it should be noted that for Pluri Inc. (PLUR), this indicator reflects market confidence in the commercialization of their 3D cell synthesis platform within the bio-industry.

Competitors of Pluri Inc. (PLUR)

Projected Price to Earnings ASND (Ascendis Pharma)|MDGL (Madrigal Pharmaceuticals Inc) - Future Price to Earnings Multiple|Future Price to Earnings Corcept CORT|RYTM - Projected Price to Earnings|Akero Therapeutics - Forward P/E Multiple|Projected Price to Earnings Ratio metsera.com|MLTX (MoonLake) - Projected Price to Earnings|CRNX: Market Cap to Future Earnings Ratio|NAMS (NewAmsterdam Pharma N.V.) - Forward P/E Multiple|Forward P/E Multiple Soleno Therapeutics Corp|Forward P/E Multiple FOLD|Future Price to Earnings ETNB (89bio.com)|Future Price to Earnings Agios Pharmaceuticals, Inc. AGIO|Structure Therapeutics Inc (GPCR) - Projected Price to Earnings Ratio|MDXG - Future Price to Earnings|RZLT: Future Price to Earnings|LXRX: Forward P/E Multiple|MBX - Market Cap to Projected Earnings|Future Price to Earnings Altimmune|Aardvark Therapeutics Inc. (AARD) - Market Cap to Projected Earnings|Future Price to Earnings Sagimet (SGMT)|Projected Price to Earnings BioAge Labs, Inc BIOA|Future Price to Earnings Biomea Fusion, Inc. BMEA|QNCX (Quince Therapeutics Inc) - Price to Expected Earnings Ratio|GUTS - Future Price to Earnings|VTVT: Future Price to Earnings|ATPC (agapeatpgroup.com) - Projected Price to Earnings|Synlogic (SYBX) - Forward P/E Multiple|Future Price to Earnings Lipocine Inc.|MTNB: Future Price to Earnings Multiple|Forward P/E Multiple SPRB|Market Cap to Projected Earnings Galecto Inc|Carmell Corp - Projected Price to Earnings|Future Price to Earnings Multiple LUMO|Organovo Holdings, Inc. - Forward P/E Multiple|Market Cap to Projected Earnings radiuspharm.com RDUS